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Background: The objective of this paper was to study antimicrobial activity and safety of Enterococcus faecium KQ
2.6 (E. faecium KQ 2.6) isolated from peacock feces.
Methods: Agar well diffusion method was adopted in antimicrobial activity assay. Disk diffusion test was used to
determine the antibiotic resistance. The identification and virulence potential of E. faecium KQ 2.6 were investigated
using PCR amplification.
Results: The results indicated that cell free supernatant (CFS) of the strain had the good antimicrobial activity against
selected gram-positive and gram-negative bacteria. The biochemical characteristics of antimicrobial substances were
investigated. The results indicated that the antimicrobial substances were still active after treatment with catalase and
proteinase, respectively. Moreover, the stability of antimicrobial substances did not change after heat treatment at 40,
50, 60, 70 and 80°C for 30 min, respectively. The activity of antimicrobial substances remained stable at 4 and −20°C
after long time storage. The antimicrobial activity of CFS was compared with that of the buffer with similar strength
and pH. The inhibitory zone of the buffer was apparently smaller than that of CFS, which meant that the acid in CFS
was not the only factor that was contributed to antibacterial activity of CFS. The antibiotic resistance and virulence
potential were evaluated using disk diffusion test and PCR amplification. The results showed that E. faecium KQ 2.6 did
not harbor any tested virulence genes such as gelE, esp, asa1, cylA, efaA and hyl. It was susceptible to most of tested
antibiotics except for vancomycin and polymyxin B.
Conclusion: E. faecium KQ 2.6 may be used as bio-preservative cultures for the production of fermented foods.
Keywords: E. faecium KQ 2.6, Antimicrobial activity, Safety evaluation, Antibiotics resistance, Virulence genesBackground
Enterococci belong to lactic acid bacteria (LAB), which
are widespread in foods and environment. In aspect of
food fermentation, it is considered that enterococci play
an important role in the development of the sensory
characteristics of fermentation foods such as sausages
and cheeses [1]. Certain cheese-makers have suggested
that enterococci can be utilized as starter cultures in the
production of Mediterranean cheese [2,3]. Furthermore,
some enterococcal strains have been successfully used as
preservatives to inhibit the growth of food spoilage* Correspondence: shilue@126.com
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unless otherwise stated.microorganisms. One of reasons that these enterococcal
strains with antimicrobial activity, produce lactic acid
[4]. Lactic acid reduces the pH that can cause the dis-
ruption of cellular substrate transport systems through
altering the cell membrane permeability or collapsing
the electrochemical proton gradient [5]. In addition, en-
terococci also can produce other antimicrobial sub-
stances such as hydrogen peroxide, bacteriocin and
bacteriocin like inhibitory substances (BLIS). In past few
years, bacteriocin has been increasingly concerned due
to its diversity and novelty. Bacteriocins are ribosomally
synthesized, extracellularly released low-molecular-mass
peptides or proteins [6,7]. Generally, most known bacte-
riocins produced by E. faecium, are small (<10 kDa),
membrane-active and unmodified peptides. One of theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proteolytic enzymes. For example, enterocin A and
enterocin B from E. faecium MMT21 are both sensitive
to trypsin, proteinase K and pronase E [8-11].
Enterococci have been used safely in foods for a long
history. However, in past few years, the concerns on the
safety of enterococci in food or feed industries have been
raised. Many studies have reported that enterococci are
associated with nosocomial infections like bacter-
aemia, endocarditis, urinary tract infections and diar-
rhea [12,13]. The main reasons that cause nosocomial
infections, are the resistance of the strains to a board
range of antibiotics and the presence of virulence fac-
tors in the strains [14]. The multiple antibiotic resist-
ant strains often cause serious infections which can’t
be cured well. In particular, vancomycin-resistant en-
terococci (VRE) have produced serious problems in
public health [15]. Virulence factors have been well
studied in recent years, and some virulence factors
have been reported in detail. The main described
factors are those are involved in adhesion, damaging tis-
sues and evasion of immune responses (capsular poly-
saccharides) [16]. Additionally, it should be mentioned
that enterococci may acquire antibiotic resistance and
virulence factors from other enterococci, since mobile
genetic elements like plasmids and transposons, can
contribute to the distribution of antibiotic resistance and
virulence factors between enterococcal strains [17,18].
Therefore, the safety evaluation of the enterococci should
be carried out before the application.
In present study, one enterococcal strain isolated from
peacock feces was identified as E. faecium KQ 2.6 by
PCR and 16S rRNA gene sequencing. Antimicrobial ac-
tivity and safety of this strain was mainly studied. The
production and biochemical properties of antimicrobial
substances were also investigated.
Methods
All chemicals were purchased from Sangon (Shanghai,
China). Indicator strains and antibiotic-containing disks
were obtained from Binhe Microorganism Reagent Co.
Ltd (Hangzhou, China). Participants in the study agreed
to carry out the following studies. No human subjects
including human material or human data, were con-
tained in present study.
Bacterial isolation and identification
Peacock feces were collected in an animal centre located
in Hangzhou Normal University. Ten-fold dilutions of
feces in sterile water were plated onto de Man, Rogosa
and Sharpe (MRS). The plates were incubated at 37°C
for 24 h. Twelve of colonies were randomly picked and
used for the study of physiological and biochemical char-
acteristics. Meanwhile, the antimicrobial activity of thestrains against Escherichia Coli was studied using the
agar spot method [19]. The strains displaying an inhib-
ition zone were selected, and maintained as stock
cultures in MRS broth supplemented with 30 % (v/v)
glycerol at −20°C.
Primers, 27 F (5′-AGAGTTGATCCTGGCTCAG-3′)
and 1492R (5′- GGTTACCTTGTTACGACTT-3′) based
on conserved regions of 16SrRNA gene were used to
direct the amplification. The program consisted of: de-
naturation at 94°C for 5 min, then 35 cycles of 94°C for
1 min, 55°C for 1 min and 72°C for 1 min followed by a
final extension at 72°C for 5 min. Amplified PCR
products were separated by 1.0 % (w/v) agarose gel
electrophoresis, and then purified with the StarPrep
Gel Extraction Kit (GenStar, Beijing, China) according
to manufacturer’s instruction. 16S rRNA gene sequen-
cing was carried out by Sunny Biotechnology Co., Ltd
(Shanghai, China).
Antimicrobial activity assay of E. faecium KQ 2.6
The antimicrobial activity of E. faecium KQ 2.6 against
pathogenic bacteria was investigated. Pathogenic bacteria
included Bacillus subtilis, Bacillus cereus, Streptococcus
pyogenes, Staphylococcus aureus, Staphylococcus epider-
midis, E. faecalis, Escherichia coli, Pseudomonas aerugi-
nosa, Klebsiella pneumoniae, Salmonella paratyphi,
Candida albicans and Aspergillus niger. The antimicro-
bial assay was performed using agar well diffusion
method [20]. Firstly, E. faecium KQ 2.6 was grown over-
night in MRS broth at 37°C. Cells in the culture were
discarded by centrifugation at 10, 000 g at 4°Cfor
20 min. 60 μL of indicator bacteria (final concentration
of 108 CFU/mL) cultured in 20 mL soft agar containing
0.80 % (w/v) agar was poured onto a solid agar plate
containing 1.5 % (w/v) agar. Afterwards, wells (8 mm in
diameter) were made on agar plate, and filled with
100 μL of cell free supernatant (CFS) of E. faecium KQ
2.6. Plates were incubated at 37°C for 24 h after being
kept for 3–4 h at 4°C. Finally, the antimicrobial activity
was analyzed by observing the clear zones around the
wells containing CFS. The clear zones were regarded as
inhibitory zones, and recorded in mm.
Growth kinetics and antimicrobial activity of E. faecium
KQ 2.6
100 mL of MRS broth was inoculated with 1.0 % (v/v) of
the culture of E. faecium KQ 2.6 and incubated at 37°C.
Optical density at 600 nm (OD600) and pH values were
monitored at 2 h intervals during 24 h. The antimicro-
bial activity assay was also performed every two hours.
To quantify the antimicrobial activity, CFS was serially
diluted 2-folds and 10 μL of each dilution was added
into the wells. The titer was defined as 2n, which is the
reciprocal of the highest dilution showing inhibition of
Table 1 Primer pairs used for detection of virulence
genes
Gene Primers (5′-3′) Size (bp) References
gelE F: TATGACAATGCTTTTTGGGAT 213 [37]
R: AGATGCACCCGAAATAATATA
esp F: AGATTTCATCTTTGATTCTTGG 510 [37]
R: AATTGATTCTTTAGCATCTGG
asa1 F: GCACGCTATTACGAACTATGA 375 [37]
R: AAGAAAGAACATCACCACGA
cylA F: ACTCGGGGATTGATAGGC 688 [37]
R: GCTGCTAAAGCTGCGCTT
efaA F: GACAGACCCTCACGAATA 705 [18]
R: AGTTCATCATGCTGTAGTA
hyl F: ACAGAAGAGCTGCAGGAAATG 276 [37]
R: GACTGACGTCCAAGTTTCCAA
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antimicrobial activity per milliliter was defined as
2n × (1,000 μL/10 μL) [21].
Effect of the biochemical factors on antimicrobial activity
E. faecium KQ 2.6 was cultivated in MRS broth at 37°C
for 16 h. CFS was obtained by centrifugation at 10,000 g
at 4°C for 20 min, and used to carry out the following
studies.
Antimicrobial activity of CFS at different temperatures
was investigated. CFS was treated at 40, 50, 60, 70 and
80°C for 30 min and 3 h, respectively, and at 121°C for
20 min. Storage stability of CFS at 4 and −20°C for 24,
48 h, 7 days and 15 days, was also performed.
The sensitivity of antimicrobial substances towards
catalase and proteinase was studied. 1.0 mL of CFS was
added to 1.0 mL of 1.0 mg/mL catalase, trypsin and pep-
sin, respectively. Afterwards, samples were incubated at
37°C for 30 min, and heated at 95°C for 5 min.
All treated samples were tested against Bacillus cereus
using agar well diffusion method. Each experiment was
performed at least two times. In addition, the antimicro-
bial activity was done using hydrogen phosphate/citric
acid buffer which had a similar pH and strength to CFS
of E. faecium KQ 2.6.
Antibiotic resistance
Disk diffusion test was used to determine the susceptibility
of E. faecium KQ 2.6 to antibiotics [22]. Antibiotic-
containing disks were those of penicillin, vancomycin,
chloramphenicol, tetracycline, erythromycin, rifampicin,
ofloxacin, polymyxin B and ciprofloxacin. 20 mL of MRS
broth containing 1.5 % agar was seeded with 200 μL of a
culture of E. faecium KQ 2.6 (106-107 CFU/mL), and
poured into a plate. Then antibiotic-containing disks were
added onto the plates according to the manufacturer’s
instructions. Inhibition zone diameters with/without
vancomycin-containing disks were measured (mm) at
37°C after 24 and 18 h incubation, respectively. Accord-
ing to the recommendation of Clinical and Laboratory
Standards Institute (CLSI), the strain was considered to
be resistant to antibiotics if the inhibition zone was
equal or smaller than 16 mm for rifampicin, 15 mm for
ciprofloxacin, 14 mm for penicillin, vancomycin and
tetracycline, 13 mm for erythromycin and ofloxacin, and
12 mm for chloramphenicol.
PCR for the detection of virulence genes
PCR amplification was used to detect virulence genes
gelE (gelatinase), esp (enterococcal surface protein), asa1
(aggregation substance), cylA (cytolysin), efaA (cell-wall
adhesion) and hyl (hyaluronidase). Primers are listed in
Table 1. The following PCR conditions were used: 94°C
for 5 min; followed by 35 cycles of 94°C for 1 min, 52°C(for gelE, efaA), 56°C (for cylA, asa1, esp) and 58°C (for
hyl) for 30 s, 72°C for 1 min; a final extension at 72°C
for 5 min. The DNA from E faecalis ATCC 29212 (asa1+,
cylA+, gelE+, efaA+ and hyl+) was used as a positive con-
trol. The amplified products were analyzed by electro-
phoresis on 1.0 % (w/v) agarose gels in 1× TAE buffer.Results
Isolation and identification of LAB strains with
antimicrobial activity
Antimicrobial activity of twelve strains isolated from
peacock feces, were studied using the agar spot method.
The results indicated that only two isolates had obvious
antimicrobial activity against Escherichia coli (data not
shown). According to the studies of physiological and
biochemical characteristics, one of two isolates could
produce gas through glucose fermentation. It was not
convenient to control the fermentation process easily.
Therefore, the strain with good antimicrobial activity
and gas-negative property, was chosen for this study.
The sequencing of the partial 16S rRNA of the strain
showed 99 % homology to that of E. faecium 3-2-31, so
it was identified as E. faecium KQ 2.6.Spectrum of antimicrobial activity
As shown in Figure 1, CFS of E. faecium KQ 2.6 could
exert inhibiting activity to the growth of Bacillus subtilis,
Bacillus cereus and Escherichia coli. The growth of a
panel of pathogenic gram-positive and gram-negative
bacteria including Bacillus subtilis, Bacillus cereus, Strepto-
coccus pyogenes, Staphylococcus epidermidis, Pseudomonas
aeruginosa, Salmonella paratyphi and E. faecalis, was also
inhibited by CFS of E. faecium KQ 2.6. However, it was not
active against fungi like Candida albicans and Aspergillsu
niger (Table 2).
Figure 1 Antimicrobial activity of CFS against Bacillus cereus, Escherichia coli and Bacillus subtilis. A: CFS of E. faecium KQ 2.6, B: Luria-Bertani broth.
Table 2 Antimicrobial activity of CFS produced by E.
faecium KQ 2.6





Bacillus subtilis LB 37 +
Bacillus cereus LB 37 +++
Streptococcus pyogenes LB 37 ++
Staphylococcus aureus LB 37 -
Staphylococcus epidermidis LB 37 ++
E. faecalis MRS 37 +
Gram-negative
Escherichia Coli LB 37 +
Pseudomonas aeruginosa LB 37 ++
Klebsiella pneumoniae LB 37 -
Salmonella paratyphi LB 37 +++
Fungi
Candida albicans PDA 28 -
Aspergillus niger PDA 28 -
aResults of antimicrobial activity were recorded in the diameter of inhibition
zones around the wells (8 mm in diameter): −, no inhibition zone; +,
zone < 5 mm; ++, zone < 5–10 mm; +++, zone > 15 mm.
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kinetics
The results of the cell density, pH of the media and pro-
duction of antimicrobial substances were obtained dur-
ing 24 h of growth at 37°C (Figure 2). During this
period, the cell density of E. faecium KQ 2.6 increased
from 0.03 to 1.37 (OD600). pH of the media dropped
down to 4.5. E. faecium KQ 2.6 began to produce anti-
microbial substances (200 AU/mL) after 4 h of growth.
Maximum values (1600 AU/mL) of antimicrobial activity
was reached at the early stationary phase (16 h), and
remained un-change in the following 8 h of growth.Characterization of antimicrobial substances
Except for heat treatment at 121°C for 20 min, the sub-
stances remained stable after heating at 40, 50, 60, 70
and 80°C for 30 min, respectively. Meanwhile, antimicro-
bial activity did not change when CFS was stored at low
temperatures(4 and −20°C) for 24, 48 h, 7 and 15 days
(Table 3). It showed that storage conditions did not led
to the decrease of antimicrobial activity significantly.
Additionally, the addition of catalase, trypsin and pepsin
to CFS had no effect on antimicrobial activity of CFS
(Table 3). The inhibitory zone of hydrogen phosphate/
Figure 2 Kinetics growth curves and production of antimicrobial substances by E. faecium KQ 2.6. ▲: OD600; ■: pH of the culture medium; black
histograms: antimicrobial activity against Bacillus cereus.
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CFS (Figure 3).
Detection of antibiotic resistance and potential virulence
factors
Phenotypic results from disk diffusion test demonstrated
that E. faecium KQ 2.6 was highly susceptible to most of
tested antibiotics such as penicillin, chloramphenicol,
tetracycline, erythromycin, rifampicin, ofloxacin and
ciprofloxacin. However, it was also found that the
strain was resistant to vancomycin and polymyxin B
(Table 4).Table 3 Effect of temperature and enzymes on the
activity of CFS of E. faecium KQ 2.6
Treatments Antimicrobial activitya
Temperature
40°C for 30 min +
50°C for 30 min +
60°C for 30 min +
70°C for 30 min +
80°C for 30 min +





a+, presence of antimicrobial activity; −, absence of antimicrobial activity;
the indicator strain, Bacillus cereusWhether the presence of virulence genes encoding
gelE, esp, asa1, cylA, efaA and hyl in the strain was in-
vestigated. The results from agarose gel electrophoresis
showed that E. faecium KQ 2.6 did not harbor virulence
genes including gelE (213 bp), esp (511 bp), asa1
(328 bp), cylA (688 bp), efaA (704 bp) and hyl (276 bp)
(Figure 4).Figure 3 Antimicrobial activity of CFS and buffer against Bacillus
cereus. A: CFS of E.faecium KQ 2.6, B: hydrogen phosphate/citric
acid buffer.
Table 4 Antibiotic resistant profile of E. faecium KQ 2.6








Polymyxin B 30 R
Ciprofloxacin 5 S
aThe antibiotic resistance was determined by disk diffusion test. The sensitive
was analyzed by the recommendation of CLSI (2008). S: sensitive; R: resistant.
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Enterococci occur in many different environments such
as in air, soil, water and the gastrointestinal tract of ani-
mals and humans. Due to the association of enterococci
with the gastrointestinal tract, it is an ordinary and effi-
cient method to screen enterococci from animal feces.
In the last decades, the benefic role of enterococci from
animal and human feces in food and animal industries
has been well studied [1,23,24]. In this study, twelve iso-
lates were screened from peacock feces, and two of them
displayed good antimicrobial properties. The highest anti-
microbial activity and gas-negative strain was named as E.
faecium KQ 2.6.
Antimicrobial activity of E. faecium KQ 2.6 was evalu-
ated. The results showed that this strain was able to in-
hibit gram-positive and gram-negative bacteria. It shouldFigure 4 Results of E. faecium KQ 2.6 using primers directed against (A) 68
(C) 213 bp fragment of the gelE gene, (D) 375 bp fragment of the asa1 ge
the hyl gene. Lane 1: standard molecular weight (2000 kb); lane 2: negative
ATCC 29212).be pointed out that many enterococci can produce bac-
teriocins, which exhibit activity towards gram-positive
and gram-negative bacteria [25]. Therefore, the hypoth-
esis that antimicrobial activity of E. faecium KQ 2.6 is
due to the produced bacteriocin, may be established.
However, the activity did not lost after CFS of E. faecium
KQ 2.6 was treated by proteinase. It demonstrated that
the antimicrobial factors were not protein components
such as bacteriocin or BLIS. The resistance of CFS to
catalase indicated that antimicrobial substance was not
hydrogen peroxide. Regarding this phenomenon, some
reports have been indicated that the antimicrobial activ-
ity may be due to the produced acid [26,27]. Anyogu
et al. [28] also indicated that the acid substances pro-
duced by E. faecium was an important factor to deter
the growth and survival of pathogens in the process of
submerged cassava fermentation. Therefore, the antimicro-
bial activity of enterococci in this study may be due to the
production of organic acids. Our results showed that the
produced acid was not the only factor that contributed to
antimicrobial activity of CFS of E. faecium KQ 2.6, since
the inhibitory zone of CFS was significantly bigger than that
of the buffer with similar pH and strength. Thus, we be-
lieved that another type of antimicrobial substance should
be in CFS of E. faecium KQ 2.6.
To study antimicrobial substances of E. faecium KQ
2.6 more specially, the heat stability and storability were
investigated. The activity could be kept stably after a
long time storage or high temperature treatment. It indi-
cated that storage conditions did not lead to the de-
crease of antimicrobial activity significantly. The high
stability of antimicrobial activity can be a good criterion8 bp fragment of the cylA gene, (B) 510 bp fragment of the esp gene,
ne, (E) 705 bp fragment of the efaA gene and (F) 276 bp fragment of
control; lane 3: E. faecium KQ 2.6; lane 4: positive control (E. faecalis
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ditions of food processing.
The incidence of antibiotic resistance has been received
high attention as it is of vital point for the safe use of the
strains in foods. It is clear that in hospital environment,
multiple antibiotic resistant strains may lead to infections
or super-infections. Enterococci are the fourth prevalent
strains causing blood infections in European hospital, and the
proportion of enterococcal infections continues to increase,
mainly because of an increasing number of antibiotic resistant
E. faecium [29]. In our study, E. faecium KQ 2.6 had resistance
to vancomycin and polymyxin B. The results indirectly agreed
with the study of Messi et al. [30]. Vancomycin-resistance
enterococci (VRE) are not restricted to clinical strains, but
can be obtained from animal organs and environment. In
last few years, the numbers of VRE have been increasing
[31]. VRE have brought treatment difficulty, as vancomycin
is the last few therapeutic options for enterococcal infec-
tions [32,33]. The mechanism of the high resistance to
vancomycin is the replacement of the terminal D-Ala of
peptidoglycan precursors with D-lactate, which can prevent
or destroy the combination between vancomycin and pep-
tidoglycan precursors [34]. Fortunately, E. faecium KQ 2.6
was sensitive to the most common antibiotics such as
penicillin, tetracycline, chloramphenicol and ciprofloxa-
cin. Therefore, the strain was not multiple antibiotic
resistant enterococci.
The investigation of antibiotic resistance alone can’t
evaluate the safety of enterococci completely. Virulence
factors are greatly contributed to enhance infection risks,
so potential virulence genes of E. faecium KQ 2.6 need
to be evaluated. It was reported that the genes encoding
adhesion-associated protein were rarely detected in E.
faecium strain from foods [18]. The absence of full Cyl
operon in E. faecium has also been reported [31]. Our
results indicated that this strain did not harbor tested
virulence genes gelE, esp, asa1, cylA, efaA and hyl, which
was in agreement with the above conclusions. In general,
the clinical enterococci harbor more virulence factors
than E. faecium KQ 2.6.
However, it should be noted that mobile genetic ele-
ments like plasmids and transposons, may contribute to
the distribution of virulence factors between enterococcci
isolated from different sources [17,18]. The virulence
genes acquisitions in E. faecium have been reported.
Clonal complex 17 lineage, a kind of E. faecium genetic
lineage, can obtain an esp gene from other clinical entero-
cocci. And this lineage not only occurs in hospital but also
is found in foods [35,36]. Another study indicated that less
than 40 % of E. faecalis proteins have been found in E.
faecium draft genome. So, E. faecium may harbor add-
itional virulence factors from E. faecalis [16]. Furthermore,
Sex pheromones or gene transfer pheromones may pro-
mote acquisition of virulence genes from otherenterococci. Even it is not a common trait that entero-
cocci produce sex pheromones or gene transfer phero-
mones [18], the work on detecting the presence of sex
pheromones or gene transfer pheromones will contrib-
ute to assess the safety of the strain.
Conclusion
To our knowledge, this is the first report on the study of
E. faecium isolated from peacock feces. E. faecium KQ
2.6 not only inhibited the growth of gram-positive bac-
teria, but also had antimicrobial activity towards gram-
negative bacteria. The antimicrobial substance was not
hydrogen peroxide or protein components. Part inhibi-
tory effect of E. faecium KQ 2.6 might be due to the pro-
duced acid. Another antimicrobial substance should be
in CFS of E. faecium KQ 2.6. E. faecium KQ 2.6 may be
considered safely for its susceptibility to most common
antibiotics and absence of the most studied virulence
genes. Therefore, this strain has potential to be used as a
food preservative in our daily life. However, it should be
further evaluated for its ability of virulence genes acqui-
sitions before this strain is applied in the food and/or
feed industries.
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